142 related articles for article (PubMed ID: 28314474)
1. Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines.
Juengel E; Euler S; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Nelson K; Bechstein WO; Blaheta RA
Phytomedicine; 2017 Apr; 27():1-7. PubMed ID: 28314474
[TBL] [Abstract][Full Text] [Related]
2. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.
Juengel E; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Tsaur I; Nelson K; Bechstein WO; Haferkamp A; Blaheta RA
Oncotarget; 2016 Dec; 7(51):85208-85219. PubMed ID: 27863441
[TBL] [Abstract][Full Text] [Related]
4. Chronic Sulforaphane Application Does Not Induce Resistance in Renal Cell Carcinoma Cells.
Rutz J; Juengel E; Euler S; Maxeiner S; Justin S; Roos F; Chun FK; Blaheta RA
Anticancer Res; 2018 Nov; 38(11):6201-6207. PubMed ID: 30396938
[TBL] [Abstract][Full Text] [Related]
5. HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.
Juengel E; Nowaz S; Makarevi J; Natsheh I; Werner I; Nelson K; Reiter M; Tsaur I; Mani J; Harder S; Bartsch G; Haferkamp A; Blaheta RA
Mol Cancer; 2014 Jun; 13():152. PubMed ID: 24935000
[TBL] [Abstract][Full Text] [Related]
6. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
Juengel E; Engler J; Natsheh I; Jones J; Mickuckyte A; Hudak L; Jonas D; Blaheta RA
BMC Cancer; 2009 May; 9():161. PubMed ID: 19473483
[TBL] [Abstract][Full Text] [Related]
7. Amygdalin inhibits the growth of renal cell carcinoma cells in vitro.
Juengel E; Thomas A; Rutz J; Makarevic J; Tsaur I; Nelson K; Haferkamp A; Blaheta RA
Int J Mol Med; 2016 Feb; 37(2):526-32. PubMed ID: 26709398
[TBL] [Abstract][Full Text] [Related]
8. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759798
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
[TBL] [Abstract][Full Text] [Related]
10. Norcantharidin counteracts acquired everolimus resistance in renal cell carcinoma by dual inhibition of mammalian target of rapamycin complex 1 and complex 2 pathways in Vitro.
Chen X; Cai X; Zheng D; Huang X; Chen Y; Deng T; Mo L; Li H; Li J; Chen S
Anticancer Drugs; 2022 Jan; 33(1):e94-e102. PubMed ID: 34261913
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma.
Chu WF; Wu DM; Liu W; Wu LJ; Li DZ; Xu DY; Wang XF
Oral Oncol; 2009 Nov; 45(11):998-1004. PubMed ID: 19589718
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane, a Dietary Isothiocyanate, Induces G₂/M Arrest in Cervical Cancer Cells through CyclinB1 Downregulation and GADD45β/CDC2 Association.
Cheng YM; Tsai CC; Hsu YC
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27626412
[TBL] [Abstract][Full Text] [Related]
13. Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.
Rutz J; Thaler S; Maxeiner S; Chun FK; Blaheta RA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218199
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
[TBL] [Abstract][Full Text] [Related]
15. The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.
Tsaur I; Makarević J; Hudak L; Juengel E; Kurosch M; Wiesner C; Bartsch G; Harder S; Haferkamp A; Blaheta RA
Cancer Lett; 2011 Dec; 313(1):84-90. PubMed ID: 21925791
[TBL] [Abstract][Full Text] [Related]
16. The effect of sulforaphane on the cell cycle, apoptosis and expression of cyclin D1 and p21 in the A549 non-small cell lung cancer cell line.
Żuryń A; Litwiniec A; Safiejko-Mroczka B; Klimaszewska-Wiśniewska A; Gagat M; Krajewski A; Gackowska L; Grzanka D
Int J Oncol; 2016 Jun; 48(6):2521-33. PubMed ID: 27035641
[TBL] [Abstract][Full Text] [Related]
17. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of sulforaphane-induced cell cycle arrest and apoptosis in human colon cancer cells.
Parnaud G; Li P; Cassar G; Rouimi P; Tulliez J; Combaret L; Gamet-Payrastre L
Nutr Cancer; 2004; 48(2):198-206. PubMed ID: 15231455
[TBL] [Abstract][Full Text] [Related]
19. Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.
Tsaur I; Thomas A; Taskiran E; Rutz J; Chun FK; Haferkamp A; Juengel E; Blaheta RA
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230567
[TBL] [Abstract][Full Text] [Related]
20. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
